Jeffrey K Aronson

27.7k total citations · 4 hit papers
327 papers, 11.6k citations indexed

About

Jeffrey K Aronson is a scholar working on Toxicology, Economics and Econometrics and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Jeffrey K Aronson has authored 327 papers receiving a total of 11.6k indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Toxicology, 59 papers in Economics and Econometrics and 53 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Jeffrey K Aronson's work include Pharmacovigilance and Adverse Drug Reactions (56 papers), Pharmaceutical studies and practices (41 papers) and Health Systems, Economic Evaluations, Quality of Life (34 papers). Jeffrey K Aronson is often cited by papers focused on Pharmacovigilance and Adverse Drug Reactions (56 papers), Pharmaceutical studies and practices (41 papers) and Health Systems, Economic Evaluations, Quality of Life (34 papers). Jeffrey K Aronson collaborates with scholars based in United Kingdom, United States and Qatar. Jeffrey K Aronson's co-authors include I. Ralph Edwards, R E Ferner, Igho Onakpoya, Carl Heneghan, Carl J Heneghan, Manfred Hauben, Jeremy Howick, Dyfrig Hughes, Paul Glasziou and Kamal R Mahtani and has published in prestigious journals such as The Lancet, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Jeffrey K Aronson

295 papers receiving 11.0k citations

Hit Papers

Adverse drug reactions: definitions, diagnosis, and manag... 2000 2026 2008 2017 2000 2012 2016 2021 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Adverse drug reactions: definitions, diagnosis, and management
    2000 2.1k citations Jeffrey K Aronson et al. profile →
  2. A new taxonomy for describing and defining adherence to medications
    2012 1.4k citations Jeffrey K Aronson et al. British Journal of Clinical Pharmacology profile →
  3. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature
    2016 426 citations Igho Onakpoya, Jeffrey K Aronson et al. profile →
  4. Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses
    2021 140 citations Jeffrey K Aronson, Richard Hobbs et al. BMJ profile →

Peers

Jeffrey K Aronson
Toine C. G. Egberts Netherlands
Jesper Hallas Denmark
Hubert G. M. Leufkens Netherlands
Miriam Sturkenboom Netherlands
Darren M. Ashcroft United Kingdom
K. Arnold Chan United States
Ian Chi Kei Wong United Kingdom
Paula A. Rochon Canada
Gianluca Trifirò Italy
Walter E. Haefeli Germany
Toine C. G. Egberts Netherlands
Jeffrey K Aronson
Citations per year, relative to Jeffrey K Aronson Jeffrey K Aronson (= 1×) peers Toine C. G. Egberts

Countries citing papers authored by Jeffrey K Aronson

Since Specialization
Citations

This map shows the geographic impact of Jeffrey K Aronson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey K Aronson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey K Aronson more than expected).

Fields of papers citing papers by Jeffrey K Aronson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey K Aronson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey K Aronson. The network helps show where Jeffrey K Aronson may publish in the future.

Co-authorship network of co-authors of Jeffrey K Aronson

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey K Aronson. A scholar is included among the top collaborators of Jeffrey K Aronson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey K Aronson. Jeffrey K Aronson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Aronson, Jeffrey K. (2025). When I use a word . . . On becoming a doctor. BMJ. 391. r2072–r2072.
2.
Aronson, Jeffrey K. (2025). When I use a word . . . Introducing hospitalists. BMJ. 391. r2473–r2473.
3.
Aronson, Jeffrey K. (2025). When I use a word . . . Medical Janus words. BMJ. 391. r2417–r2417. 1 indexed citations
4.
5.
Sartori, Daniele, et al.. (2024). A Comparison of Signals of Designated Medical Events and Non-designated Medical Events: Results from a Scoping Review. Drug Safety. 47(5). 475–485. 1 indexed citations
6.
Aronson, Jeffrey K, Carl Heneghan, & R E Ferner. (2023). Drug shortages. Part 1. Definitions and harms. British Journal of Clinical Pharmacology. 89(10). 2950–2956. 8 indexed citations
7.
Aronson, Jeffrey K, Carl Heneghan, & R E Ferner. (2023). Drug shortages. Part 2: Trends, causes and solutions. British Journal of Clinical Pharmacology. 89(10). 2957–2963. 9 indexed citations
8.
Parepalli, Sai Arathi, et al.. (2022). Placebo's invisible brother: a restricted scoping review of the biomedical literature on the nocebo effect. Pain. 163(11). 2103–2111. 5 indexed citations
9.
Aronson, Jeffrey K. (2022). When I use a word . . . . Bioscience journals—an open and shut case?. BMJ. 376. o536–o536.
10.
Richards, Georgia C., Jeffrey K Aronson, Brian MacKenna, et al.. (2022). Sales of Over-the-Counter Products Containing Codeine in 31 Countries, 2013–2019: A Retrospective Observational Study. Drug Safety. 45(3). 237–247. 13 indexed citations
11.
Aronson, Jeffrey K. (2022). When I use a word . . . . Listening to the patient. BMJ. 376. o646–o646. 3 indexed citations
12.
Aronson, Jeffrey K. (2022). When I use a word . . . . Medical magic. BMJ. 377. o1092–o1092.
13.
Aronson, Jeffrey K. (2021). When I use a word . . . . The efficiency paradox. BMJ. 375. n2712–n2712.
14.
Taylor, Kathryn, Kamal R Mahtani, & Jeffrey K Aronson. (2021). Dealing with categorical risk data when extracting data for meta-analysis. BMJ evidence-based medicine. 26(2). 43–45. 3 indexed citations
15.
Darwich, Adam S., Thomas M. Polasek, Jeffrey K Aronson, et al.. (2020). Model-Informed Precision Dosing: Background, Requirements, Validation, Implementation, and Forward Trajectory of Individualizing Drug Therapy. The Annual Review of Pharmacology and Toxicology. 61(1). 225–245. 109 indexed citations
16.
Aronson, Jeffrey K, et al.. (2020). The problem of look‐alike, sound‐alike name errors: Drivers and solutions. British Journal of Clinical Pharmacology. 87(2). 386–394. 37 indexed citations
17.
Aronson, Jeffrey K, Carl Heneghan, & R E Ferner. (2019). Medical Devices: Definition, Classification, and Regulatory Implications. Drug Safety. 43(2). 83–93. 58 indexed citations
18.
Green, A. Richard, Peter Haddad, & Jeffrey K Aronson. (2018). Marketing medicines: charting the rise of modern therapeutics through a systematic review of adverts in UK medical journals (1950–1980). British Journal of Clinical Pharmacology. 84(8). 1668–1685. 5 indexed citations
19.
20.
Aronson, Jeffrey K, et al.. (2005). NICE proposes to withdraw Alzheimer's drugs from NHS. BMJ. 330(7494). 759.3–759.3. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Toine C. G. Egberts Breakdown of academic impact, for papers by Jesper Hallas Breakdown of academic impact, for papers by Hubert G. M. Leufkens Breakdown of academic impact, for papers by Miriam Sturkenboom Breakdown of academic impact, for papers by Darren M. Ashcroft Breakdown of academic impact, for papers by K. Arnold Chan Breakdown of academic impact, for papers by Ian Chi Kei Wong Breakdown of academic impact, for papers by Paula A. Rochon Breakdown of academic impact, for papers by Gianluca Trifirò Breakdown of academic impact, for papers by Walter E. Haefeli
Rankless by CCL
2026